A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma

The primary objective is to compare the relative dose potency of HFA vs CFC pMDI budesonide on airway responsiveness to methacholine.